Product Developer News

Product Developer News

  • 01.30.2025  |  Nowe finansowanie dla terapii CMTX-101 – nadzieja na skuteczniejsze leczenie infekcji płuc w mukowiscydozie

    Firma Clarametyx Biosciences, specjalizująca się w innowacyjnych terapiach przeciwbakteryjnych, otrzymała wsparcie finansowe od funduszu Kineticos AMR Accelerator Fund (KAMRA Fund).

    Full Story

  • 01.30.2025  |  Clarametyx Biosciences receives investment from Kineticos AMR Accelerator Fund

    Clarametyx Biosciences, a Columbus, OH-based clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, received an investment from Kinetics AMR Accelerator Fund.

    Full Story

  • 01.29.2025  |  Neues Antibiotikum wird in Gießen entwickelt

    Die Naturstoff-Forschungsgruppe der Justus-Liebig-Universität Gießen erhält rund 950 000 Euro von der Initiative CARB-X.

    Full Story

  • 01.29.2025  |  Gießen im Kampf gegen Resistenzen: Neues Antibiotikum in Entwicklung!

    Die Naturstoff-Forschungsgruppe der Justus-Liebig-Universität Gießen erhält rund 950.000 Euro von der Initiative CARB-X zur Entwicklung eines neuartigen Antibiotikums.

    Full Story

  • 01.28.2025  |  CARB-X funds Rhode Island Hospital to assess feasibility of direct from blood detection of bacterial pneumonia

    CARB-X will award Rhode Island Hospital at Brown University Health US$1M to demonstrate proof-of-concept of a polymerase chain reaction (PCR) approach informed by RNA sequencing to detect bacterial pneumonia directly from whole blood.

    Full Story

  • 01.28.2025  |  Rhode Island Hospital wins $1M from CARB-X for molecular pneumonia blood test

    CARB-X announced Tuesday that it has awarded $1 million to Rhode Island Hospital at Brown University Health to support proof-of-concept studies of a direct-from-blood PCR test informed by RNA sequencing to detect pneumonia-causing bacteria.

    Full Story

  • 01.28.2025  |  Rhode Island Hospital wins $1M from CARB-X for molecular pneumonia blood test

    CARB-X announced Tuesday that it has awarded $1 million to Rhode Island Hospital at Brown University Health to support proof-of-concept studies of a direct-from-blood PCR test informed by RNA sequencing to detect pneumonia-causing bacteria.

    Full Story

  • 01.28.2025  |  CARB-X funds development of novel pneumonia diagnostic

    CARB-X announced today that it is awarding $1 million to Rhode Island Hospital at Brown University Health to develop a test to diagnose bacterial pneumonia from whole blood.

    Full Story

  • 01.23.2025  |  Vedanta Biosciences publishes additional phase 2 VE303 results in Nature Medicine

    BIOSPACE | VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms. Analyses identified predictors of VE303 colonization and protection from CDI recurrence. Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026.

    Full Story

  • 01.23.2025  |  CARB-X funds development of monoclonal antibody for Staph aureus

    CIDRAP | CARB-X announced today that it is awarding $729,000 to Chicago-based biotechnology company Immunartes to develop a monoclonal antibody designed to prevent Staphylococcus aureus infections.

    Full Story

  • 01.23.2025  |  Debiopharm et GARDP signent un accord pour lutter contre l’antibiorésistance

    LE TEMPS | L’entreprise pharmaceutique vaudoise et l’organisation basée à Genève ont annoncé un partenariat pour soutenir le développement d’un nouvel antibiotique contre la gonorrhée.

    Full Story

  • 01.21.2025  |  Mehr Geld für Antibiotikaforschung in Gießen

    AERZTEBLATT | Die Justus-Liebig-Universität Gießen (JLU) erhält von der Initiative CARB-X rund 950.000 Euro in der ersten Förderrunde für die Entwicklung von Molekülen zur Hemmung eines spezifischen Proteins gramnegativer Bakterien.

    Full Story

  • 01.17.2025  |  CARB-X funds peptide antibiotic

    CARB-X announced yesterday that it is awarding $610,000 to Justus Liebig University Giessen in Germany to develop a first-in-class peptide antibiotic.

    Full Story

  • 01.15.2025  |  Visby Medical secures additional $3.9M from CARB-X to fight antibiotic resistance with PCR-based mutation detection at the POC

    Visby Medical, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from CARB-X to accelerate its fight against antibiotic resistance.

    Full Story

  • 01.14.2025  |  Nationwide Children’s spinoff targeting antibiotic resistance starts developing vaccine

    A Nationwide Children's Hospital spinoff is developing a vaccine based on the same biotechnology it's testing as an antibody treatment attacking chronic drug-resistant infections.

    Full Story

  • 01.14.2025  |  Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea

    The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae.

    Full Story

  • 01.14.2025  |  CARB-X grants Melio $3.5M for neonatal sepsis rest, Visby wins additional $3.9M

    CARB-X announced Tuesday that it will fund diagnostics firm Melio $3.5 million to develop a rapid assay for the detection of neonatal sepsis. In a separate announcement on Wednesday, Visby Medical announced that it has received $3.9 million in additional funding from CARB-X to support its point-of-care gonorrhea assay using instrument-free PCR.

    Full Story

  • 01.14.2025  |  CARB-X funds rapid diagnostic test platform for bloodstream infections

    CARB-X today announced an award of $3.5 million to biotechnology company Melio to develop a rapid diagnostic test for bloodstream infections, including neonatal sepsis.

    Full Story

  • 01.14.2025  |  CARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis

    CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis.

    Full Story

  • 01.10.2025  |  Peptilogics receives $3.3 million from CARB-X to develop treatment for fracture-related infections

    CARB-X yesterday announced an award of $3.3 million to Pittsburgh-based Peptilogics to develop a slow-release version of its investigational, broad-spectrum therapeutic for joint-related infections.

    Full Story

  • 01.09.2025  |  CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections

    CARB-X will award Peptilogics US$3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.

    Full Story

  • 01.09.2025  |  Seres Therapeutics announces new translational biomarker results from SER-155 Phase 1b clinical study and provides corporate updates

    Seres Therapeutics, a leading live biotherapeutics company, today announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled study in patients undergoing allogenic stem cell transplantation (allo-HSCT).

    Full Story

  • 01.08.2025  |  Basilea provides portfolio update and outlook

    Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones.

    Full Story